Cargando…
Genomic analysis of response to bacillus Calmette-Guérin (BCG) treatment in high-grade stage 1 bladder cancer patients
BACKGROUND: Intravesical bacillus Calmette-Guérin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine patient selection. We performed genomic analysis on high-grade (...
Autores principales: | Sanders, J. Alexa, Frasier, Connor, Matulay, Justin T., Steuerwald, Nury M., Zhu, Jason, Grigg, Claud M., Kearns, James T., Riggs, Stephen B., Gaston, Kris E., Brouwer, Cory R., Burks, R. Tucker, Hartman, Aaron L., Foureau, David M., Burgess, Earle F., Clark, Peter E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350238/ https://www.ncbi.nlm.nih.gov/pubmed/34430403 http://dx.doi.org/10.21037/tau-21-158 |
Ejemplares similares
-
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951) -
Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018) -
Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021) -
Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency
por: Al-Hammadi, Suleiman, et al.
Publicado: (2017) -
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)